11:19 AM EDT, 10/07/2024 (MT Newswires) -- Trinity Biotech ( TRIB ) shares rose 9% in recent trading Monday after the company said its first pre-pivotal clinical trial in Europe for its next-generation continuous glucose monitor, or CGM, confirmed that the refined sensor achieved a mean absolute relative difference comparable to previous models.

The outcome validates the enhancements made since acquiring the technology from Waveform Technologies in January, Trinity Biotech ( TRIB ) said, adding that a second pre-pivotal trial is planned for Q4, before a pivotal trial in 2025.

Price: 1.31, Change: +0.11, Percent Change: +9.17